SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Man holds up his hand to signify a pause or stop
Regulatory
Kezar’s Lupus Trial Paused After Four Patient Deaths
The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.
October 7, 2024
 · 
2 min read
 · 
Tristan Manalac
3D Rendering of a Natural Killer Cell (NK Cell) destroying a cancer cell
Cancer
TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO
After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious optimism.
October 7, 2024
 · 
6 min read
 · 
Gail Dutton
Fractal art representing inside the gut, airways, or blood vessels, possibly infected with disease and viruses, or it could be a rocky cave on an alien planet.
Weight loss
Can CB1 Inhibitors Make a Comeback in Obesity?
After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo Nordisk, Corbus Pharmaceuticals and Skye Bioscience are betting that a new mechanism of action will improve the safety profile.
October 7, 2024
 · 
6 min read
 · 
Jill Drachenberg
Young Woman Standing In Front Of Exit Door. Full Length, Vector, Illustration, Flat Design, Character.
Layoffs
Relay Therapeutics to Lay Off 10% of Workforce
Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.
October 4, 2024
 · 
1 min read
 · 
Angela Gabriel
Central Coast New South Wales Australia – May 21, 2024 Assortment of weight loss and diabetic drugs on the table
Editorial
Obesity Drug Shortage Ends for Lilly, Continues for Novo as Industry Bolsters Manufacturing
Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the insatiable demand for weight loss drugs.
October 4, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Blue Sanofi sign on building in Germany at night
Rare diseases
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.
October 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Update: AbbVie headquarters building in California
Earnings
AbbVie Trims Full-Year Earnings Guidance Due to R&D Milestone Costs
The company is lowering its previously issued guidance for 2024 adjusted earnings per share by $0.04 per share to account for acquired in-process research and development expenses incurred for acquisitions and collaborations in the third quarter.
October 4, 2024
 · 
1 min read
 · 
Tristan Manalac
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Approvals
BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC
Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of overtreatment with this type of therapeutic regimen with platinum-doublet chemotherapy.
October 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Gloved hand holding a vial of mpox vaccine
Vaccines
Bavarian Nordic’s Mpox Shot Shows Antibody Responses Wane After 6 to 12 Months: Study
While a JAMA study found a decline in mpox antibody responses after vaccination, a University of Oxford expert cautioned that there is still not enough evidence to determine if this decline also leads to waning protections.
October 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS